Business Context and Reporting Period
LivaNova PLC filed this Form 8-K on February 21, 2018, to disclose a strategic shift involving the sale of its Cardiac Rhythm Management (CRM) Business Franchise. The filing provides recast unaudited financial information for the nine months ended September 30, 2017, and the twelve months ended December 31, 2016, to reflect the CRM results as discontinued operations under U.S. GAAP.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It states that the recast classification of CRM as a discontinued operation had no effect on the net income (loss) for the periods previously reported in the Company's Form 10-Q and Form 10-K filings. The document references a proposed sale price of $190.0 million in cash for the CRM business.
Material Changes
- Discontinued Operations: The Company concluded that the sale of the CRM business qualifies as a discontinued operation due to the strategic shift in future operations.
- Financial Recasting: Historical financial statements for the nine months ended September 30, 2017, and the year ended December 31, 2016, have been recast to segregate CRM results, though total net income remains unchanged.
Guidance, Outlook, and Risks
- Transaction Status: The Company entered into a letter of intent on November 20, 2017, to sell the CRM business to MicroPort Scientific Corporation for $190.0 million.
- Closing Conditions: Completion is subject to employee works council consultations, regulatory approvals, and Hong Kong Stock Exchange Major Transaction requirements.
- Timeline: The transaction is expected to close in the second quarter of 2018.
- Non-GAAP Measures: The Company utilizes non-GAAP financial measures for performance monitoring, which are reconciled to GAAP counterparts on its Investor Relations page.
Investor Verification Checklist
- Verify the definitive acquisition agreement status and completion of employee works council consultations.
- Confirm receipt of all necessary regulatory approvals, including Hong Kong Stock Exchange requirements.
- Review the detailed recast financial statements and non-GAAP reconciliations available on the Company's Investor Relations website.
- Monitor the expected closing date in the second quarter of 2018 for any delays.